·¢²¼Ê±¼ä : ÐÇÆÚÁù ÎÄÕÂUSP40-NF35ͨÓÃÕ½ÚĿ¼¸üÐÂÍê±Ï¿ªÊ¼ÔĶÁ7070c15b5bcfa1c7aa00b52acfc789eb172d9e32
USP29-ͨÓÃÕ½ÚÖ¸µ¼Ä¿Â¼(¸½Â¼) µÚ9Ò³ ¹²7Ò³
£¼1061£¾COLOR¡ªINSTRUMENTAL MEASUREMENT ÏÔÉ«£ÒÇÆ÷²âÁ¿
£¼1063£¾SHEAR CELL METHODOLOGY FOR POWDER FLOW TESTING ·ÛÄ©Á÷¶¯ÊÔÑéµÄ¼ôÇз½·¨ £¼1064£¾IDENTIFICATION OF ARTICLES OF BOTANICAL ORIGIN BY HIGH-PERFORMANCE THIN-LAYER CHROMATOGRAPHY PROCEDURE ͨ¹ý¸ßÐÔÄܵı¡²ãÉ«Æ×·¨¼ø¶¨Ö²ÎïÔÁÏ £¼1065£¾Ion Chromatography Àë×ÓÉ«Æ×·¨
£¼1066£¾PHYSICAL ENVIRONMENTS THAT PROMOTE SAFE MEDICATION USE ÎïÀí»·¾³´Ùʹ°²È«Ê¹ÓÃÒ©Îï
£¼1072£¾DISINFECTANTS AND ANTISEPTICS Ïû¶¾¼ÁºÍ·À¸¯¼Á
£¼1074£¾EXCIPIENT BIOLOGICAL SAFETY EVALUATION GUIDELINES ¸³ÐμÁ£¨¸¨ÁÏ£©ÉúÎﰲȫÐÔÆÀ¹ÀÖ¸µ¼
£¼1078£¾GOOD MANUFACTURING PRACTICES FOR BULK PHARMACEUTICAL EXCIPIENTS
ÅúÒ©Æ·¸³ÐμÁµÄÉú²ú¹ÜÀí¹æ·¶
£¼1079£¾Good Storage and Shipping Practices Á¼ºÃµÄÖü´æÓëÔËÊä¹æ·¶
£¼1080£¾BULK PHARMACEUTICAL EXCIPIENTS¡ªCERTIFICATE OF ANALYSIS ÅúÒ©Æ·¸³ÐμÁ-COA
£¼1084£¾GLYCOPROTEIN AND GLYCAN ANALYSIS¡ªGENERAL CONSIDERATIONS
Ìǵ°°×ºÍ¶àÌÇ·ÖÎö-Ò»°ãͨÔò
£¼1086£¾IMPURITIES IN DRUG SUBSTANCES AND DRUG PRODUCTS Ò©ÎïºÍÒ©Îï²úÆ·ÖеÄÔÓÖÊ £¼1087£¾APPARENT INTRINSIC DISSOLUTION¡ªDISSOLUTION TESTING PROCEDURES FOR
ROTATING DISK AND STATIONARY DISK ÄÚ²¿µÄÈܳö¶È-ÐýתºÍ¾²Ö¹Èܳö¼ì²â³ÌÐò£¿
£¼1088£¾IN VITRO AND IN VIVO EVALUATION OF DOSAGE FORMS ÌåÄÚÓëÌåÍâµÄ¼ÁÐ͵ÄÆÀ¹À £¼1090£¾ASSESSMENT
OF
DRUG
PRODUCT
PERFORMANCE-BIOAVAILABILITY,
BIOEQUIVALENCE, AND DISSOLUTION Ò©Îï²úÆ·ÐÔÄÜÆÀ¹À£ºÉúÎïÀûÓöȡ¢ÉúÎïµÈЧÐÔºÍÈܳö £¼1091£¾LABELING OF INACTIVE INGREDIENTS ·Ç»îÐԳɷֵıêʾ
£¼1092£¾THE DISSOLUTION PROCEDURE: DEVELOPMENT AND VALIDATION Èܳö³ÌÐò£º¿ª·¢ÓëÑéÖ¤
£¼1094£¾CAPSULES¡ªDISSOLUTION TESTING AND RELATED QUALITY ATTRIBUTES ½ºÄÒ-¹ØÓÚ²úÆ·ÖÊÁ¿µÄÈܳö²â¶¨
£¼1097£¾BULK POWDER SAMPLING PROCEDURES£º·ÛÄ©ÑùÆ·È¡Ñù³ÌÐò £¼1102£¾IMMUNOLOGICAL TEST METHODS¡ªGENERAL CONSIDERATIONS ÃâÒß²âÊÔ·½·¨-×ÜÔò
£¼1103£¾IMMUNOLOGICAL TEST METHODS¡ªENZYME-LINKED IMMUNOSORBENT ASSAY
(ELISA) ÃâÒßѧ²âÊÔ·½·¨-øÁªÃâÒßÎü¸½²â¶¨
£¼1104£¾IMMUNOLOGICAL TEST METHODS¡ªIMMUNOBLOT ANALYSIS
ÃâÒß²âÊÔ·½·¨-ÃâÒßÓ¡¼£·¨
9
USP29-ͨÓÃÕ½ÚÖ¸µ¼Ä¿Â¼(¸½Â¼) µÚ10Ò³ ¹²7Ò³
£¼1105£¾IMMUNOLOGICAL TEST METHODS¡ªSURFACE PLASMON RESONANCE ÃâÒß²âÊÔ·½·¨-±íÃæµÈÀë×ÓÌå¹²Õñ
£¼1106£¾IMMUNOGENICITY ASSAYS¡ªDESIGN AND VALIDATION OF IMMUNOASSAYS TO
DETECT ANTI-DRUG ANTIBODIES
£¿
£¼1106.1£¾IMMUNOGENICITY ASSAYS¡ªDESIGN AND VALIDATION OF ASSAYS TO DETECT ANTI-DRUG NEUTRALIZING ANTIBODY ÃâÒßÔÐԲⶨ¡ª¿¹ÑªÇåÖп¹Ìå²â¶¨ÊÔÑéµÄÉè¼Æ¼°ÑéÖ¤ £¼1111£¾MICROBIOLOGICAL EXAMINATION OF NONSTERILE PRODUCTS: ACCEPTANCE
CRITERIA FOR PHARMACEUTICAL PREPARATIONS AND SUBSTANCES FOR PHARMACEUTICAL USE
·ÇÎÞ¾ú²úÆ·µÄ΢ÉúÎïѧ¼ì²é£ºÒ©ÓÃÖƼÁºÍÖÆÒ©¹ý³ÌʹÓõÄÎïÖʽÓÊܱê×¼
£¼1112£¾MICROBIAL CHARACTERIZATION, IDENTIFICATION, AND STRAIN TYPING ·ÇÎÞ¾úÒ©Îï²úÆ·Ë®»îÐԲⶨӦÓÃ
£¼1113£¾MICROBIOLOGICAL ATTRIBUTES OF NONSTERILE PHARMACEUTICAL PRODUCTS
·ÇÎÞ¾úÒ©Æ·ÖеÄ΢ÉúÎï·Ö²¼
£¼1115£¾BIOBURDEN CONTROL OF NONSTERILE DRUG SUBSTANCES AND PRODUCTS ·ÇÎÞ¾úÒ©ÎïºÍ²úÆ·µÄÉúÎ︺ÔØ¿ØÖÆ
£¼1116£¾MICROBIOLOGICAL CONTROL AND MONITORING OF ASEPTIC PROCESSING
ENVIRONMENTS ½à¾»µÄ·¿¼äÓëÆäËü¿É¿Ø»·¾³µÄ΢ÉúÎïÆÀ¹À
£¼1117£¾MICROBIOLOGICAL BEST LABORATORY PRACTICES ΢ÉúÎï×îÓÅʵÑéÊҹ淶 £¼1118£¾MONITORING DEVICES¡ªTIME, TEMPERATURE, AND HUMIDITY
¼à¿Ø×°Öãʱ¼ä¡¢Î¶ÈÓëʪ¶È
£¼1119£¾NEAR-INFRARED SPECTROPHOTOMETRY ½üºìÍâ·Ö¹â¹â¶È²â¶¨·¨ £¼1120£¾Raman Spectrophotometry ÀÂü·Ö¹â¹â¶È²â¶¨·¨ £¼1121£¾NOMENCLATURE ÃüÃû
£¼1125£¾NUCLEIC ACID-BASED TECHNIQUES¡ªGENERAL ºËËá¼¼Êõ-ͨÔò
£¼1126£¾NUCLEIC ACID-BASED TECHNIQUES¡ªEXTRACTION, DETECTION, AND SEQUENCING ºËËá¼¼Êõ-ÌáÈ¡¡¢¼ì²â¡¢²âÐò
£¼1127£¾NUCLEIC ACID-BASED TECHNIQUES¡ªAMPLIFICATION ºËËá¼¼Êõ-À©Ôö £¼1128£¾NUCLEIC ACID-BASED TECHNIQUES¡ªMICROARRAY ºËËá¼¼Êõ-΢ÕóÁÐ £¼1129£¾NUCLEIC ACID-BASED TECHNIQUES¡ªGENOTYPING ºËËá¼¼Êõ-»ùÒò·ÖÐÍ
£¼1130£¾NUCLEIC ACID-BASED TECHNIQUES¡ªAPPROACHES FOR DETECTING TRACE
NUCLEIC ACIDS (RESIDUAL DNA TESTING)
ºËËá¼¼Êõ-̽²â΢Á¿ºËËáµÄÓ¦Ó㨲ÐÁôDNA²âÊÔ£©
£¼1132£¾Residual Host Cell Protein Measurement in Biopharmaceuticals ÉúÎïÖÆÒ©ÖвÐÁôËÞÖ÷ϸ°ûµ°°×µÄ
10
USP29-ͨÓÃÕ½ÚÖ¸µ¼Ä¿Â¼(¸½Â¼) µÚ11Ò³ ¹²7Ò³
²â¶¨
£¼1136£¾PACKAGING AND REPACKAGING¡ªSINGLE-UNIT CONTAINERS
°ü×°ºÍÔÙ°ü×°£µ¥Ò»ÈÝÆ÷
£¼1151£¾PHARMACEUTICAL DOSAGE FORMS Ò©Îï¼ÁÐÍ
£¼1152£¾ANIMAL DRUGS FOR USE IN ANIMAL FEEDS ÊÞÒ©ÔÚ¶¯ÎïËÇÁÏÖеÄʹÓà £¼1160£¾PHARMACEUTICAL CALCULATIONS IN PRESCRIPTION COMPOUNDING °´´¦·½»ìºÏµÄÒ©ÎïµÄ¼ÆËã
£¼1163£¾QUALITY ASSURANCE IN PHARMACEUTICAL COMPOUNDING
°´´¦·½»ìºÏµÄÒ©ÎïµÄÖÊÁ¿±£Ö¤
£¼1171£¾PHASE-SOLUBILITY ANALYSIS ÏàÈܽâ·ÖÎö £¼1174£¾Powder Flow ·ÛÄ©Á÷¶¯ÐÔ
£¼1176£¾PRESCRIPTION BALANCES AND VOLUMETRIC APPARATUS ´¦·½ÌìƽÓëÈÝÁ¿Æ÷¾ß £¼1177£¾Good Packaging Practices Á¼ºÃµÄ°ü×°²Ù×÷ £¼1178£¾Good Repackaging Practices Á¼ºÃµÄÔÙ°ü×°²Ù×÷ £¼1180£¾HUMAN PLASMA ÈËѪ½¬
£¼1181£¾SCANNING ELECTRON MICROSCOPY ɨÃèµç×ÓÏÔ΢¾µ £¼1184£¾SENSITIZATION TESTING ÖÂÃô²âÊÔ
£¼1191£¾STABILITY CONSIDERATIONS IN DISPENSING PRACTICE ·Ö×°²Ù×÷ÖÐÎȶ¨ÐÔ¿¼²ì £¼1195£¾SIGNIFICANT CHANGE GUIDE FOR BULK PHARMACEUTICAL EXCIPIENTS É¢×°Ò©Óø¨Áϸü»»Ö¸µ¼ÔÔò
£¼1197£¾GOOD DISTRIBUTION PRACTICES FOR BULK PHARMACEUTICAL EXCIPIENTS
É¢×°Ò©Óø¨ÁÏÁ¼ºÃµÄ·Ö×°²Ù×÷
£¼1207£¾STERILE PRODUCT PACKAGING¡ªINTEGRITY EVALUATION ÎÞ¾ú²úÆ·°ü×°£ÍêÕûÐÔÆÀ¹À
£¼1207.1£¾PACKAGE INTEGRITY TESTING IN THE PRODUCT LIFE CYCLE¡ªTEST METHOD SELECTION AND VALIDATION ²úÆ·ÉúÃüÖÜÆÚÖаü×°ÍêÕûÐÔ²âÊÔ¡ª²âÊÔ·½·¨µÄÑ¡ÔñºÍÑéÖ¤
£¼1207.2£¾PACKAGE INTEGRITY LEAK TEST TECHNOLOGIES °ü×°ÍêÕûÐÔй¶ÊÔÑé²âÊÔ¼¼Êõ £¼1207.3£¾PACKAGE SEAL QUALITY TEST TECHNOLOGIES°ü×°ÃÜ·âÖÊÁ¿²âÊÔ¼¼Êõ £¼1208£¾STERILITY TESTING¡ªVALIDATION OF ISOLATOR SYSTEMS ÎÞ¾úʵÑ飸ôÀëϵͳµÄÑéÖ¤
£¼1209£¾STERILIZATION¡ªCHEMICAL AND PHYSICOCHEMICAL INDICATORS AND
INTEGRATORS Ãð¾ú£»¯Ñ§ÓëÎïÀí»¯Ñ§µÄָʾ¼ÁÒÔ¼°¶þÕßµÄ×ۺϣ¨±¾°æ±¾ÒÑɾ³ý£©
£¼1211£¾STERILIZATION AND STERILITY ASSURANCE OF COMPENDIAL ARTICLES
Ò©µäÎïÆ·ÖеÄÃð¾úÓëÃð¾ú±£Ö¤
£¼1216£¾TABLET FRIABILITY Ƭ¼ÁµÄ´àËé¶È £¼1217£¾TABLET BREAKING FORCE Ƭ¼Á¶ÏÁÑÁ¦
£¼1222£¾TERMINALLY STERILIZED PHARMACEUTICAL PRODUCTS¡ªPARAMETRIC RELEASE
Ò©Æ·ÖÕ¶ËÃð¾ú£·ÅÐвÎÊý
11
USP29-ͨÓÃÕ½ÚÖ¸µ¼Ä¿Â¼(¸½Â¼) µÚ12Ò³ ¹²7Ò³
£¼1223£¾VALIDATION OF ALTERNATIVE MICROBIOLOGICAL METHODS
¿É¹©Ñ¡ÔñµÄ΢ÉúÎïѧ·½·¨µÄÑéÖ¤
£¼1223.1£¾VALIDATION OF ALTERNATIVE METHODS TO ANTIBIOTIC MICROBIAL ASSAYS ¿¹ÉúËØ΢ÉúÎï²â¶¨µÄ±¸Ñ¡·½·¨µÄÑéÖ¤
£¼1224£¾TRANSFER OF ANALYTICAL PROCEDURES ·ÖÎö·½·¨×ªÒÆ £¼1225£¾VALIDATION OF COMPENDIAL METHODSÒ©µä·½·¨µÄÑéÖ¤ £¼1226£¾VERIFICATION OF COMPENDIAL PROCEDURES Ò©µä·½·¨µÄÈ·ÈÏ
£¼1227£¾VALIDATION OF MICROBIAL RECOVERY FROM PHARMACOPEIAL ARTICLES ´ÓÒ©ÎïÖлØÊÕ΢ÉúÎïµÄÑéÖ¤
£¼1228£¾DEPYROGENATION È¥³ýÈÈÔ·¨
£¼1228.1£¾DRY HEAT DEPYROGENATION¸ÉÈÈÈ¥³ýÈÈÔ·¨
£¼1228.3£¾DEPYROGENATION BY FILTRATIONͨ¹ý¹ýÂËÈ¥³ýÈÈÔ·¨
£¼1228.5£¾ENDOTOXIN INDICATORS FOR DEPYROGENATION È¥³ýÈÈÔϸ¾úÄÚ¶¾ËØָʾ¼Á £¼1229£¾STERILIZATION OF COMPENDIAL ARTICLES Ò©µäÃð¾ú¹ý³Ì £¼1229.1£¾STEAM STERILIZATION BY DIRECT CONTACT Ö±½ÓÕôÆûÃð¾ú
£¼1229.2£¾MOIST HEAT STERILIZATION OF AQUEOUS LIQUIDS Ë®ÈÜÒºµÄʪÈÈÃð¾ú £¼1229.3£¾MONITORING OF BIOBURDEN ÉúÎ︺Ôؼà¿Ø
£¼1229.4£¾STERILIZING FILTRATION OF LIQUIDS ÈÜÒºµÄÎÞ¾ú¹ýÂËÆ÷ £¼1229.5£¾BIOLOGICAL INDICATORS FOR STERILIZATIONÃð¾úÉúÎïָʾ¼Á £¼1229.6£¾LIQUID-PHASE STERILIZATION Һ̬Ãð¾ú £¼1229.7£¾GASEOUS STERILIZATION Æø̬Ãð¾ú £¼1229.8£¾DRY HEAT STERILIZATION ¸ÉÈÈÃð¾ú
£¼1229.9£¾PHYSICOCHEMICAL INTEGRATORS AND INDICATORS FOR STERILIZATION Ãð¾úÎïÀí»¯Ñ§Ö¸Ê¾¼Á
£¼1229.10£¾RADIATION STERILIZATION ·øÉäÃð¾ú £¼1229.11£¾VAPOR PHASE STERILIZATIONÕôÆûÃð¾ú £¼1229.12£¾NEW STERILIZATION METHODSеÄÃð¾ú·½·¨ £¼1229.13£¾STERILIZATION-IN-PLACEÃð¾ú
£¼1230£¾WATER FOR HEMODIALYSIS APPLICATIONS ѪҺ͸Îö¹ý³ÌÓÃË® £¼1231£¾WATER FOR PHARMACEUTICAL PURPOSES ÖÆÒ©ÓÃË®
£¼1234£¾VACCINES FOR HUMAN USE¡ªPOLYSACCHARIDE AND GLYCOCONJUGATE VACCINES ÈËÓÃÒßÃç-¶àÌǺÍÌǸ´ºÏÎïÒßÃç
£¼1235£¾VACCINES FOR HUMAN USE¡ªGENERAL CONSIDERATIONS ÈËÓÃÒßÃç-ͨÔò £¼1237£¾VIROLOGY TEST METHODS ²¡¶¾²âÊÔ·½·¨
£¼1238£¾VACCINES FOR HUMAN USE¡ªBACTERIAL VACCINES ÈËÓÃÒßÃç-ϸ¾úÒßÃç £¼1240£¾VIRUS TESTING OF HUMAN PLASMA FOR FURTHER MANUFACTURE ÏÂÒ»²½Ê¹ÓÃÈËѪ½¬µÄ²¡¶¾²âÊÔ
12